tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Gerber DA et al. Immunosuppressive agents: recent developments in molecular action and clinical application. 1998 Transplant. Proc. pmid:9636637
Schneeberger H et al. Tacrolimus as a primary immunosuppressive therapy in cadaveric renal transplantation: five years' experience at a single center. 1998 Transplant. Proc. pmid:9636642
Resch K and Szamel M Molecular mechanisms of the immunosuppressive action of cyclosporin A. 1997 Sep-Oct Int. J. Immunopharmacol. pmid:9637358
Baldari CT et al. NF-AT-luciferase reporter T cell lines as tools to screen immunosuppressive drugs. 1998 Biologicals pmid:9637743
Abraham RT Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling. 1998 Curr. Opin. Immunol. pmid:9638370
Takahara S et al. A comparative study of FK506 granules and capsules in renal transplant recipients. 1998 Transpl. Int. pmid:9638846
Morris-Stiff G and Jurewicz WA Single centre experience with mycophenolate mofetil for refractory rejection in cadaveric renal transplantation. 1998 Transpl. Int. pmid:9638849
Murray M et al. Comparison of tacrolimus absorption in transplant patients receiving continuous versus interrupted enteral nutritional feeding. 1998 Ann Pharmacother pmid:9640479
Kuwata T et al. A role of calcineurin in coreceptor regulation during differentiation of Cd4+Cd8+ T cells. 1998 Biochem. Biophys. Res. Commun. pmid:9642110
Gruessner RW et al. Suggested guidelines for the use of tacrolimus in pancreas/kidney transplantation. 1998 Clin Transplant pmid:9642520
Gabe SM et al. The effect of tacrolimus (FK506) on intestinal barrier function and cellular energy production in humans. 1998 Gastroenterology pmid:9649460
Canzanello VJ et al. Late hypertension after liver transplantation: a comparison of cyclosporine and tacrolimus (FK 506). 1998 Liver Transpl Surg pmid:9649648
Friberg H et al. Cyclosporin A, but not FK 506, protects mitochondria and neurons against hypoglycemic damage and implicates the mitochondrial permeability transition in cell death. 1998 J. Neurosci. pmid:9651198
Tarumi K et al. The plasma FK506-binding protein 12 level is related to acute cellular rejection in small bowel transplantation. 1998 Immunopharmacol Immunotoxicol pmid:9653668
Kommers T et al. Regulation of the phosphorylation of glial fibrillary acidic protein (GFAP) by glutamate and calcium ions in slices of immature rat spinal cord: comparison with immature hippocampus. 1998 Neurosci. Lett. pmid:9654363
Cetinkale O et al. Involvement of neutrophils in ischemia-reperfusion injury of inguinal island skin flaps in rats. 1998 Plast. Reconstr. Surg. pmid:9655420
Matsui H et al. [Physiological role of calcineurin in central nervous system]. 1998 Tanpakushitsu Kakusan Koso pmid:9655961
Tamura K [Multiple actions of tacrolimus and cyclosporin A as specific inhibitors of calcineurin]. 1998 Tanpakushitsu Kakusan Koso pmid:9655970
Morozumi K et al. [Current topics of the rejection pathology in human renal allografts]. 1998 Hinyokika Kiyo pmid:9656109
Nishioka T et al. [Is tacrolimus effective for ongoing renal allograft rejection?]. 1998 Hinyokika Kiyo pmid:9656112
Sasa H et al. Hepatic extraction of tacrolimus in rats with experimental liver diseases. 1998 Biol. Pharm. Bull. pmid:9657047
Le Bihan S et al. Calcium/calmodulin kinase inhibitors and immunosuppressant macrolides rapamycin and FK506 inhibit progestin- and glucocorticosteroid receptor-mediated transcription in human breast cancer T47D cells. 1998 Mol. Endocrinol. pmid:9658403
Fujino T et al. The immunosuppressive compound FK506 does not affect expulsion of Echinostoma trivolvis in C3H mice. 1998 Parasitol. Res. pmid:9660146
McBride WJ et al. Allogeneic fetal intestinal transplantation with FK506 immunosuppression. 1998 J. Pediatr. Surg. pmid:9660232
Bader G et al. Reduction of cyclosporine-induced gingival overgrowth following a change to tacrolimus. A case history involving a liver transplant patient. 1998 J. Periodontol. pmid:9660343
Tsujikawa A et al. Tacrolimus (FK506) attenuates leukocyte accumulation after transient retinal ischemia. 1998 Stroke pmid:9660400
Lai MM et al. Cain, a novel physiologic protein inhibitor of calcineurin. 1998 J. Biol. Chem. pmid:9660798
Nagayasu T et al. Expression of proliferating cell nuclear antigen in bronchial epithelium after lung transplantation in the rat. 1998 J. Heart Lung Transplant. pmid:9662091
Stockwell BR and Schreiber SL TGF-beta-signaling with small molecule FKBP12 antagonists that bind myristoylated FKBP12-TGF-beta type I receptor fusion proteins. 1998 Chem. Biol. pmid:9662508
Kokado Y et al. Low-dose tacrolimus (FK506)-based immunosuppressive protocol in living donor renal transplantation. 1998 Transpl. Int. pmid:9664945
Hauser IA and Neumayer HN Tacrolimus and cyclosporine efficacy in high-risk kidney transplantation. European Multicentre Tacrolimus (FK506) Renal Study Group. 1998 Transpl. Int. pmid:9664948
Morris-Stiff G et al. Conversion of renal transplant recipients from cyclosporin to low-dose tacrolimus for refractory rejection. 1998 Transpl. Int. pmid:9664949
Morris-Stiff G et al. Conversion of renal transplant recipients from cyclosporin (neoral) to tacrolimus (prograf) for haemolytic uraemic syndrome. 1998 Transpl. Int. pmid:9664954
Kyo M et al. Morphological findings in non-episode biopsies of kidney transplant allografts treated with FK506 or cyclosporine. 1998 Transpl. Int. pmid:9664955
Hernández-Herrera G et al. Tacrolimus rescue therapy for cyclosporine-induced nephrotoxicity. 1998 Transpl. Int. pmid:9664956
Margarit C et al. Efficacy and safety of oral low-dose tacrolimus treatment in liver transplantation. 1998 Transpl. Int. pmid:9664992
Pou L et al. Influence of posttransplant time on dose and concentration of tacrolimus in liver transplant patients. 1998 Transpl. Int. pmid:9664994
Reggiani P et al. Rescue FK506 early conversion for refractory rejection after pediatric liver transplantation: experience in 20 children. 1998 Transpl. Int. pmid:9664995
Jara P et al. Tacrolimus for steroid-resistant liver rejection in children. 1998 Transpl. Int. pmid:9664996
Horimoto H et al. Transplantation tolerance by a combined therapy with sulfatide, anti-LFA-1/ICAM-1 monoclonal antibodies and FK506 in rat cardiac transplantation. 1998 Transpl. Int. pmid:9665003
Charco R et al. Early use of tacrolimus as rescue therapy for refractory liver allograft rejection. 1998 Transpl. Int. pmid:9665004
Zhang JG et al. Differential effects of cyclosporin A and tacrolimus on the production of TGF-beta: implications for the development of obliterative bronchiolitis after lung transplantation. 1998 Transpl. Int. pmid:9665007
Peter C et al. Does tacrolimus cause more severe anemia than cyclosporine A in children after renal transplantation? 1998 Transpl. Int. pmid:9665008
Morris-Stiff G et al. Prospective randomised study comparing tacrolimus (Prograf) and cyclosporin (Neoral) as primary immunosuppression in cadaveric renal transplants at a single institution: interim report of the first 80 cases. 1998 Transpl. Int. pmid:9665010
Romero E et al. [Tacrolimus and hypertrophic cardiomyopathy]. 1998 Med Clin (Barc) pmid:9666425
Horigome A et al. Tacrolimus-induced apoptosis and its prevention by interleukins in mitogen-activated human peripheral-blood mononuclear cells. 1998 Immunopharmacology pmid:9667420
Takamatsu Y et al. IL-13 production by peripheral blood mononuclear cells from patients with atopic dermatitis. 1998 Dermatology (Basel) pmid:9669111
Gross A et al. Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. 1998 EMBO J. pmid:9670005
Polak J et al. Primary pulmonary hypertension: pathologist as patient. 1998 May-Jun J R Coll Physicians Lond pmid:9670148
Trindade E et al. Use of granulocyte macrophage colony stimulating factor in children after orthotopic liver transplantation. 1998 J. Hepatol. pmid:9672183
Yamada H et al. Simvastatin-tacrolimus and simvastatin-cyclosporin interactions in rats. 1998 Biopharm Drug Dispos pmid:9673778
Yardin C et al. FK506 antagonizes apoptosis and c-jun protein expression in neuronal cultures. 1998 Neuroreport pmid:9674596
Salowe SP and Hermes JD Competitive and slow-binding inhibition of calcineurin by drug x immunophilin complexes. 1998 Arch. Biochem. Biophys. pmid:9675023
Onuma H et al. A calcineurin inhibitor, FK506, blocks voltage-gated calcium channel-dependent LTP in the hippocampus. 1998 Neurosci. Res. pmid:9678635
Fisher NC et al. Chronic renal failure following liver transplantation: a retrospective analysis. 1998 Transplantation pmid:9679823
Sanchez-Campos S et al. Cholestasis and alterations of glutathione metabolism induced by tacrolimus (FK506) in the rat. 1998 Transplantation pmid:9679826
Denesyuk AI et al. Analogous conformations of both binding and effector regions in cyclosporin A, FK506 and rapamycin. 1998 Comput. Chem. pmid:9680690
Van Leent EJ et al. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. 1998 Arch Dermatol pmid:9681343
Hultsch T et al. Direct evidence that FK506 inhibition of FcepsilonRI-mediated exocytosis from RBL mast cells involves calcineurin. 1998 Arch. Dermatol. Res. pmid:9681677
Grupp C et al. Haemolytic uraemic syndrome (HUS) during treatment with cyclosporin A after renal transplantation--is tacrolimus the answer? 1998 Nephrol. Dial. Transplant. pmid:9681701
Peces R et al. Alloimmune haemolytic anaemia resulting from anti-A and anti-B antibody induced by group O graft in renal transplant recipients. 1998 Nephrol. Dial. Transplant. pmid:9681751
Medh RD et al. Agonist-specific modulation of glucocorticoid receptor-mediated transcription by immunosuppressants. 1998 Mol. Cell. Endocrinol. pmid:9685211
Tsuzuki S et al. FK506 (tacrolimus) inhibits extravasation of lymphoid cells by abrogating VLA-4/VCAM-1 mediated transendothelial migration. 1998 FEBS Lett. pmid:9688583
Kilmartin DJ et al. Tacrolimus (FK506) in failed cyclosporin A therapy in endogenous posterior uveitis. 1998 Ocul. Immunol. Inflamm. pmid:9689640
Ding JM et al. A neuronal ryanodine receptor mediates light-induced phase delays of the circadian clock. 1998 Nature pmid:9690474
Moriwaki A et al. An immunosuppressant, FK506, protects against neuronal dysfunction and death but has no effect on electrographic and behavioral activities induced by systemic kainate. 1998 Neuroscience pmid:9692722
Mihatsch MJ et al. The side-effects of ciclosporine-A and tacrolimus. 1998 Clin. Nephrol. pmid:9696431
Rejto PA and Verkhivker GM Molecular anchors with large stability gaps ensure linear binding free energy relationships for hydrophobic substituents. 1998 Pac Symp Biocomput pmid:9697196
[Tacrolimus in kidney transplantation. Bürgenstock, Switzerland, 20 March 1998]. 1998 Dtsch. Med. Wochenschr. pmid:9697633
Matsumoto T et al. Influence of FK506 on experimental atherosclerosis in cholesterol-fed rabbits. 1998 Atherosclerosis pmid:9699896
Duraj F et al. [Intestinal transplantation. The first Swedish transplantation of the small intestine in an adult patient with pseudoobstruction]. 1998 Lakartidningen pmid:9700261
Gruessner RW et al. Donor-specific portal blood transfusion in intestinal transplantation: a prospective, preclinical large animal study. 1998 Transplantation pmid:9701258
Garg UC et al. Comparison of the Abbott IMx Tacrolimus I and Tacrolimus II assays. 1998 Clin. Chem. pmid:9702984
Xu M et al. Effect of peritransplant FTY720 alone or in combination with post-transplant tacrolimus in a rat model of cardiac allotransplantation. 1998 Transpl. Int. pmid:9704394
Stone JH et al. Outcome of renal transplantation in ninety-seven cyclosporine-era patients with systemic lupus erythematosus and matched controls. 1998 Arthritis Rheum. pmid:9704643
Ogawa T et al. Osteoblastic differentiation is enhanced by rapamycin in rat osteoblast-like osteosarcoma (ROS 17/2.8) cells. 1998 Biochem. Biophys. Res. Commun. pmid:9705862
Khattab A et al. Cyclosporins: lack of correlation between antischistosomal properties and inhibition of cyclophilin isomerase activity. 1998 Exp. Parasitol. pmid:9709036
White MH et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. 1998 Clin. Infect. Dis. pmid:9709879
Ruetz S Yeast secretory vesicle system for expression and functional characterization of P-glycoproteins. 1998 Meth. Enzymol. pmid:9711569
Marsaud V et al. Dexamethasone and triamcinolone acetonide accumulation in mouse fibroblasts is differently modulated by the immunosuppressants cyclosporin A, FK506, rapamycin and their analogues, as well as by other P-glycoprotein ligands. 1998 J. Steroid Biochem. Mol. Biol. pmid:9712407
Moreno M et al. Monitoring of tacrolimus as rescue therapy in pediatric liver transplantation. 1998 Ther Drug Monit pmid:9712459
Holt DW and Johnston A Monitoring new immunosuppressive agents. Are the methods adequate? 1997 Drug Metabol Drug Interact pmid:9713574
Shaw LM Mycophenolate mofetil: pharmacokinetic strategies for optimizing immunosuppression. 1997 Drug Metabol Drug Interact pmid:9713576
Zini R et al. Tacrolimus decreases in vitro oxidative phosphorylation of mitochondria from rat forebrain. 1998 Life Sci. pmid:9714423
Iizuka K et al. InsP3, but not novel Ca2+ releasers, contributes to agonist-initiated contraction in rabbit airway smooth muscle. 1998 J. Physiol. (Lond.) pmid:9714870
Tamura F et al. FK506 promotes liver regeneration by suppressing natural killer cell activity. 1998 J. Gastroenterol. Hepatol. pmid:9715421
Fukuda K et al. cFKBP/SMAP; a novel molecule involved in the regulation of smooth muscle differentiation. 1998 Development pmid:9716519
Tao HR FK506 inhibits severe graft-versus-host disease without mediating the involvement of perforin and granzyme B. 1998 Hokkaido Igaku Zasshi pmid:9719949
Jacobson P et al. Tacrolimus: a new agent for the prevention of graft-versus-host disease in hematopoietic stem cell transplantation. 1998 Bone Marrow Transplant. pmid:9720734
Yang X et al. Essential role of CED-4 oligomerization in CED-3 activation and apoptosis. 1998 Science pmid:9721101
Srivastava M et al. Drug-associated acute-onset vanishing bile duct and Stevens-Johnson syndromes in a child. 1998 Gastroenterology pmid:9721172
Oellerich M et al. Therapeutic drug monitoring of cyclosporine and tacrolimus. Update on Lake Louise Consensus Conference on cyclosporin and tacrolimus. 1998 Clin. Biochem. pmid:9721427
Soldin SJ Role of immunophilins in therapeutic drug monitoring of immunosuppressive drugs. 1998 Clin. Biochem. pmid:9721438
Gruessner RW et al. Mycophenolate mofetil in pancreas transplantation. 1998 Transplantation pmid:9721799
Terakura M et al. Lymphoid/nonlymphoid compartmentalization of donor leukocyte chimerism in rat recipients of heart allografts, with or without adjunct bone marrow. 1998 Transplantation pmid:9721804
Glicklich D et al. Chronic renal allograft rejection: no response to mycophenolate mofetil. 1998 Transplantation pmid:9721811
Calandra S Sinus arrest during tacrolimus treatment: was the QT interval prolonged? 1998 Transplantation pmid:9721813
Kahan BD High variability of drug exposure: a biopharmaceutic risk factor for chronic rejection. 1998 Transplant. Proc. pmid:9723224
Keown PA and Primmett DR Cyclosporine: the principal immunosuppressant for renal transplantation. 1998 Transplant. Proc. pmid:9723252
Armenti VT et al. Pregnancy outcomes in female renal transplant recipients. 1998 Transplant. Proc. pmid:9723259